NasdaqGS - Delayed Quote
USD
Royalty Pharma plc (RPRX)
63.96
+0.08
(+0.13%)
At close: September 4 at 4:00:00 PM EDT
60.50
-3.46
(-5.41%)
After hours: September 4 at 7:55:13 PM EDT
Trade RPRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for RPRX
- Previous Close
63.88 - Open
63.43 - Bid 58.75 x 200
- Ask 69.02 x 200
- Day's Range
63.43 - 64.38 - 52 Week Range
34.08 - 64.38 - Volume
3,372,439 - Avg. Volume
3,008,608 - Market Cap (intraday)
36.958B - Beta (5Y Monthly) 0.43
- PE Ratio (TTM)
34.39 - EPS (TTM)
1.86 - Earnings Date (est.) Nov 4, 2026
- Forward Dividend & Yield 0.94 (1.47%)
- Ex-Dividend Date Aug 14, 2026
- 1y Target Est
64.75
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RPRX
67.80%
S&P 500 (^GSPC)
12.75%
1-Year Return
RPRX
76.69%
S&P 500 (^GSPC)
18.71%
3-Year Return
RPRX
128.11%
S&P 500 (^GSPC)
70.93%
5-Year Return
RPRX
82.87%
S&P 500 (^GSPC)
70.18%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/3/2026
-
Market Cap
28.45B
-
Enterprise Value
35.69B
-
Trailing P/E
34.35
-
Forward P/E
32.57
-
PEG Ratio (5yr expected)
1.49
-
Price/Sales (ttm)
14.06
-
Price/Book (mrq)
4.16
-
Enterprise Value/Revenue
14.07
-
Enterprise Value/EBITDA
20.84
Financial Highlights
Profitability and Income Statement
-
Profit Margin
32.02%
-
Return on Assets (ttm)
5.09%
-
Return on Equity (ttm)
13.97%
-
Revenue (ttm)
2.54B
-
Net Income Avi to Common (ttm)
811.99M
-
Diluted EPS (ttm)
1.86
Balance Sheet and Cash Flow
-
Total Cash (mrq)
836.99M
-
Total Debt/Equity (mrq)
91.58%
-
Levered Free Cash Flow (ttm)
-1.2B
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Royalty Pharma Earnings: New Growth Drivers Support Durable Royalty Receipts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice Target -
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice Target -
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice Target -
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice Target
